These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 18275817)

  • 1. Biochemical and structural studies of ASPP proteins reveal differential binding to p53, p63, and p73.
    Robinson RA; Lu X; Jones EY; Siebold C
    Structure; 2008 Feb; 16(2):259-68. PubMed ID: 18275817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insight into the structural basis of pro- and antiapoptotic p53 modulation by ASPP proteins.
    Ahn J; Byeon IL; Byeon CH; Gronenborn AM
    J Biol Chem; 2009 May; 284(20):13812-13822. PubMed ID: 19246451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural basis for ASPP2 recognition by the tumor suppressor p73.
    Canning P; von Delft F; Bullock AN
    J Mol Biol; 2012 Nov; 423(4):515-27. PubMed ID: 22917970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ASPP1 and ASPP2: common activators of p53 family members.
    Bergamaschi D; Samuels Y; Jin B; Duraisingham S; Crook T; Lu X
    Mol Cell Biol; 2004 Feb; 24(3):1341-50. PubMed ID: 14729977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. iASPP inhibits p53-independent apoptosis by inhibiting transcriptional activity of p63/p73 on promoters of proapoptotic genes.
    Cai Y; Qiu S; Gao X; Gu SZ; Liu ZJ
    Apoptosis; 2012 Aug; 17(8):777-83. PubMed ID: 22538442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular interactions of ASPP1 and ASPP2 with the p53 protein family and the apoptotic promoters PUMA and Bax.
    Patel S; George R; Autore F; Fraternali F; Ladbury JE; Nikolova PV
    Nucleic Acids Res; 2008 Sep; 36(16):5139-51. PubMed ID: 18676979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The ASPP interaction network: electrostatic differentiation between pro- and anti-apoptotic proteins.
    Benyamini H; Friedler A
    J Mol Recognit; 2011; 24(2):266-74. PubMed ID: 20623514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flexible Tethering of ASPP Proteins Facilitates PP-1c Catalysis.
    Zhou Y; Millott R; Kim HJ; Peng S; Edwards RA; Skene-Arnold T; Hammel M; Lees-Miller SP; Tainer JA; Holmes CFB; Glover JNM
    Structure; 2019 Oct; 27(10):1485-1496.e4. PubMed ID: 31402222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural evolution of p53, p63, and p73: implication for heterotetramer formation.
    Joerger AC; Rajagopalan S; Natan E; Veprintsev DB; Robinson CV; Fersht AR
    Proc Natl Acad Sci U S A; 2009 Oct; 106(42):17705-10. PubMed ID: 19815500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abnormal expression pattern of the ASPP family of proteins in human non-small cell lung cancer and regulatory functions on apoptosis through p53 by iASPP.
    Li S; Shi G; Yuan H; Zhou T; Zhang Q; Zhu H; Wang X
    Oncol Rep; 2012 Jul; 28(1):133-40. PubMed ID: 22552744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular mechanisms underlying the interaction of protein phosphatase-1c with ASPP proteins.
    Skene-Arnold TD; Luu HA; Uhrig RG; De Wever V; Nimick M; Maynes J; Fong A; James MN; Trinkle-Mulcahy L; Moorhead GB; Holmes CF
    Biochem J; 2013 Feb; 449(3):649-59. PubMed ID: 23088536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human.
    Bergamaschi D; Samuels Y; O'Neil NJ; Trigiante G; Crook T; Hsieh JK; O'Connor DJ; Zhong S; Campargue I; Tomlinson ML; Kuwabara PE; Lu X
    Nat Genet; 2003 Feb; 33(2):162-7. PubMed ID: 12524540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction of regulators Mdm2 and Mdmx with transcription factors p53, p63 and p73.
    Zdzalik M; Pustelny K; Kedracka-Krok S; Huben K; Pecak A; Wladyka B; Jankowski S; Dubin A; Potempa J; Dubin G
    Cell Cycle; 2010 Nov; 9(22):4584-91. PubMed ID: 21088494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic prospects for p73 and p63: rising from the shadow of p53.
    Vilgelm A; El-Rifai W; Zaika A
    Drug Resist Updat; 2008; 11(4-5):152-63. PubMed ID: 18801697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. P53 family: at the crossroads in cancer therapy.
    Alsafadi S; Tourpin S; André F; Vassal G; Ahomadegbe JC
    Curr Med Chem; 2009; 16(32):4328-44. PubMed ID: 19754415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p63 and p73: roles in development and tumor formation.
    Moll UM; Slade N
    Mol Cancer Res; 2004 Jul; 2(7):371-86. PubMed ID: 15280445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The p73 DNA binding domain displays enhanced stability relative to its homologue, the tumor suppressor p53, and exhibits cooperative DNA binding.
    Patel S; Bui TT; Drake AF; Fraternali F; Nikolova PV
    Biochemistry; 2008 Mar; 47(10):3235-44. PubMed ID: 18260640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conformational stability and activity of p73 require a second helix in the tetramerization domain.
    Coutandin D; Löhr F; Niesen FH; Ikeya T; Weber TA; Schäfer B; Zielonka EM; Bullock AN; Yang A; Güntert P; Knapp S; McKeon F; Ou HD; Dötsch V
    Cell Death Differ; 2009 Dec; 16(12):1582-9. PubMed ID: 19763140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Redox state of p63 and p73 core domains regulates sequence-specific DNA binding.
    Tichý V; Navrátilová L; Adámik M; Fojta M; Brázdová M
    Biochem Biophys Res Commun; 2013 Apr; 433(4):445-9. PubMed ID: 23501101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of Daxx interacting with p73, one of the p53 family, and its regulation of p53 activity by competitive interaction with PML.
    Kim EJ; Park JS; Um SJ
    Nucleic Acids Res; 2003 Sep; 31(18):5356-67. PubMed ID: 12954772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.